Form 4: Vir Bio Director Sells 22,000 Shares Under 10b5-1 Plan

Vir Biotechnology Director Vicki L. Sato sold 22,000 shares of common stock for approximately $4.99 per share as part of a pre-arranged 10b5-1 trading plan.

Summary

• Vicki L. Sato, a Director of Vir Biotechnology, Inc. (VIR), sold 22,000 shares of common stock.
• The transaction occurred on September 2, 2025.
• The shares were sold at a weighted average price of $4.9914, with individual sales ranging from $4.88 to $5.07.
• Following this transaction, Ms. Sato beneficially owns 1,254,391 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on March 27, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be seen as slightly negative, the fact that it's part of a pre-arranged 10b5-1 plan mitigates any strong negative signal, as it's a scheduled event rather than a reaction to new information.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on recent material non-public information.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived as a slight negative signal regarding insider sentiment, though the impact is mitigated by the pre-planned nature.

Stakeholder Impact

• Shareholders may note the director's sale, but the pre-arranged nature via a 10b5-1 plan suggests it is a routine liquidity event rather than a signal of declining confidence.

Key Dates

Recommendation

The filing reports a routine insider sale under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of a significant change in the company's fundamental outlook or the insider's long-term confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Vir Biotechnology, VIR, Vicki L. Sato, Insider Sale, Form 4, 10b5-1 Plan, Director Transaction, Equity Sale